Attached files
| file | filename |
|---|---|
| EX-99.4 - EX-99.4 - WebMD Health Corp. | d246513dex994.htm |
| EX-99.1 - EX-99.1 - WebMD Health Corp. | d246513dex991.htm |
| EX-99.2 - EX-99.2 - WebMD Health Corp. | d246513dex992.htm |
| 8-K - 8-K - WebMD Health Corp. | d246513d8k.htm |
Exhibit 99.3
WEBMD HEALTH CORP.
FINANCIAL GUIDANCE FOR THE YEAR ENDING DECEMBER 31, 2016
(In millions, except per share amounts)
| Guidance Range | ||||||||
| Revenue |
||||||||
| Advertising and sponsorship |
||||||||
| Biopharma and medical device |
$ | 421.0 | $ | 434.0 | ||||
| OTC, CPG and other |
128.0 | 133.0 | ||||||
|
|
|
|
|
|||||
| 549.0 | 567.0 | |||||||
| Private portal services |
109.0 | 110.0 | ||||||
| Information services |
27.0 | 28.0 | ||||||
|
|
|
|
|
|||||
| $ | 685.0 | $ | 705.0 | |||||
|
|
|
|
|
|||||
| Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) (a) |
$ | 219.0 | $ | 230.0 | ||||
| Interest, taxes, non-cash and other items (b) |
||||||||
| Interest expense, net |
(18.0 | ) | (18.0 | ) | ||||
| Depreciation and amortization |
(35.0 | ) | (33.0 | ) | ||||
| Non-cash stock-based compensation |
(36.0 | ) | (33.0 | ) | ||||
|
|
|
|
|
|||||
| Income before income tax provision |
130.0 | 146.0 | ||||||
| Income tax provision |
(51.0 | ) | (57.0 | ) | ||||
|
|
|
|
|
|||||
| Net income |
$ | 79.0 | $ | 89.0 | ||||
|
|
|
|
|
|||||
| Income per share: |
||||||||
| Basic |
$ | 2.09 | $ | 2.32 | ||||
|
|
|
|
|
|||||
| Diluted (c) |
$ | 1.75 | $ | 1.90 | ||||
|
|
|
|
|
|||||
| Calculation of income per share: |
||||||||
| Net income (numerator for basic income per share) |
$ | 79.0 | $ | 89.0 | ||||
| Add-back of interest expense, net of tax, related to: |
||||||||
| 1.50% convertible notes |
3.5 | 3.5 | ||||||
| 2.50% convertible notes |
7.2 | 7.2 | ||||||
| 2.25% convertible notes |
0.4 | 0.4 | ||||||
|
|
|
|
|
|||||
| Numerator for diluted income per share |
$ | 90.1 | $ | 100.1 | ||||
|
|
|
|
|
|||||
| Weighted average shares outstanding (denominator for basic income per share) |
37.8 | 38.3 | ||||||
| Stock options and restricted stock |
1.5 | 2.0 | ||||||
| Weighted average shares issuable upon conversion of: |
||||||||
| 1.50% convertible notes |
5.7 | 5.7 | ||||||
| 2.50% convertible notes |
6.2 | 6.2 | ||||||
| 2.25% convertible notes |
0.4 | 0.4 | ||||||
|
|
|
|
|
|||||
| Denominator for diluted income per share |
51.6 | 52.6 | ||||||
|
|
|
|
|
|||||
| (a) | See Annex A—Explanation of Non-GAAP Financial Measures |
| (b) | Reconciliation of Adjusted EBITDA to net income |
| (c) | See Supplemental 2016 Guidance for Income Per Share Calculation below |
Additional information regarding forecast for the quarter ending March 31, 2016:
| - | Revenue is forecasted to be between $154.5 million to $157.5 million |
| - | Revenue distribution is forecasted to be approximately 56% from Biopharma and medical device; 21% from OTC, CPG and other; 18.5% from private portal services and 4.5% from information services |
| - | Adjusted EBITDA is forecasted to be between $43.5 million to $45.5 million |
| - | Net income is forecasted to be between $13.2 million to $14.7 million |
The above guidance does not include the impact if any, of future deployment of capital for items such as share repurchases, convertible note repurchases or acquisitions, any future gains or losses from discontinued operations, any future gains or losses on investments, and other future non-recurring, one-time or unusual items.
WEBMD HEALTH CORP.
SUPPLEMENTAL 2016 GUIDANCE FOR INCOME PER SHARE CALCULATION
Based on the Company’s Financial Guidance for the Year Ending December 31, 2016, the 1.50% convertible notes, the 2.50% convertible notes and the 2.25% convertible notes are expected to be dilutive to net income on both the low end and high end of the full year guidance range. Additionally, each of the series of convertible notes may be dilutive in certain quarters, depending on the amount of net income for such quarter. The following table contains the approximate level of net income for an individual quarter and for the full year 2016 at which each of the series of convertible notes would become dilutive to income per share. To the extent this net income is exceeded for any such period, the table also includes the amounts by which the numerator and denominator should each be adjusted for purposes of the diluted income per share calculation.
| Quarterly Amounts | Annual Amounts | |||||||||||||||||||||||
| All amounts in millions | 1.50% Convertible Notes |
2.50% Convertible Notes |
2.25% Convertible Notes (a) |
1.50% Convertible Notes |
2.50% Convertible Notes |
2.25% Convertible Notes (a) |
||||||||||||||||||
| Approximate net income at which convertible notes become dilutive (b) |
$ | 6.0 | $ | 12.2 | $ | 13.4 | $ | 23.9 | $ | 48.7 | $ | 53.7 | ||||||||||||
| Interest expense, net of tax to add-back to net income (numerator) |
$ | 0.9 | $ | 1.8 | $ | 0.4 | $ | 3.5 | $ | 7.2 | $ | 0.4 | ||||||||||||
| Additional shares to include in weighted-average diluted share count (denominator) |
5.7 | 6.2 | 1.4 | 5.7 | 6.2 | 0.4 | ||||||||||||||||||
| (a) | Since the 2.25% convertible notes will mature on March 31, 2016, the quarterly amounts above are only applicable for the quarter ending March 31, 2016. Additionally, the Annual Amounts column reflects the impact of the additional shares for the 2.25% convertible notes, weighted for the period that they will be outstanding during the year ending December 31, 2016. |
| (b) | These net income amounts assume a weighted-average diluted share count of 39.3 million shares attributable to common shares, stock options and restricted stock (prior to the effect of convertible notes) and are subject to change as such weighted-average share count changes. |